137 related articles for article (PubMed ID: 11766987)
1. Contribution of specific transport systems to anthracycline transport in tumor and normal cells.
Nagasawa K; Nagai K; Ohnishi N; Yokoyama T; Fujimoto S
Curr Drug Metab; 2001 Dec; 2(4):355-66. PubMed ID: 11766987
[TBL] [Abstract][Full Text] [Related]
2. Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells.
Nagasawa K; Fumihara T; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1999 Jul; 90(7):781-7. PubMed ID: 10470292
[TBL] [Abstract][Full Text] [Related]
3. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1997 Aug; 88(8):750-9. PubMed ID: 9330607
[TBL] [Abstract][Full Text] [Related]
4. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
5. Comparison of uptake mechanisms for anthracyclines in human leukemic cells.
Karim H; Bogason A; Bhuiyan H; Fotoohi AK; Lafolie P; Vitols S
Curr Drug Deliv; 2013 Aug; 10(4):404-12. PubMed ID: 23062181
[TBL] [Abstract][Full Text] [Related]
6. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
[TBL] [Abstract][Full Text] [Related]
7. Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1998 Jun; 89(6):673-80. PubMed ID: 9703366
[TBL] [Abstract][Full Text] [Related]
8. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin.
Sugiyama T; Sadzuka Y; Nagasawa K; Ohnishi N; Yokoyama T; Sonobe T
Jpn J Cancer Res; 1999 Jul; 90(7):775-80. PubMed ID: 10470291
[TBL] [Abstract][Full Text] [Related]
9. Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system.
Nagai K; Nagasawa K; Fujimoto S
Cancer Chemother Pharmacol; 2005 Mar; 55(3):222-30. PubMed ID: 15526202
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
11. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.
Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920
[TBL] [Abstract][Full Text] [Related]
12. Contribution of an unidentified sodium-dependent nucleoside transport system to the uptake and cytotoxicity of anthracycline in mouse M5076 ovarian sarcoma cells.
Nagai K; Nagasawa K; Koma M; Kihara Y; Fujimoto S
Biochem Pharmacol; 2006 Feb; 71(5):565-73. PubMed ID: 16376308
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
14. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake of pirarubicin, daunorubicin and doxorubicin.
Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
Biol Pharm Bull; 1994 Sep; 17(9):1305-8. PubMed ID: 7841960
[TBL] [Abstract][Full Text] [Related]
15. The role of bioreductive activation of antitumour anthracycline drugs in cytotoxic activity against sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
Eur J Pharmacol; 2012 Jan; 674(2-3):112-25. PubMed ID: 22115891
[TBL] [Abstract][Full Text] [Related]
16. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
17. [Anthracycline transport in sensitive and resistant leukemia cells].
Erttmann R; Erb N; Forcadell de Dios P; Neurath C; Looft G; Landbeck G
Klin Padiatr; 1989; 201(1):40-5. PubMed ID: 2704176
[TBL] [Abstract][Full Text] [Related]
18. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis by idarubicin: how important is the plasma peak?
Gieseler F; Clark M; Stiebeling K; Puschmann M; Valsamas S
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):217-21. PubMed ID: 10783832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
